Impact of Fidaxomicin De-Restriction on Clostridioides difficile Episodes in Hospitalized Pediatric Cellular Therapy Patients

Clicks: 12
ID: 327288
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #121 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Pediatric patients undergoing cellular therapy (CT) with hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy are vulnerable to Clostridioides difficile infection (CDI). Recent guidelines recommend fidaxomicin treatment for first and recurrent uncomplicated CDI episodes in this population, though pediatric real-world data is limited. Fidaxomicin is narrower spectrum, dosed less frequently, and can be used for shorter durations versus enteral vancomycin. In 2023, Children’s Hospital Los Angeles (CHLA) updated hospital CDI guidelines, allowing CT providers to order fidaxomicin without approval from the antimicrobial stewardship program. This study evaluated the impact of this intervention on CDI episodes in hospitalized CT patients. Methods Data were extracted for patients admitted to the CHLA HCT unit with CDI in the pre- (Nov 2021-Nov 2023) and post-intervention (Dec 2023-Sep 2025) periods. De-restriction of fidaxomicin was implemented 12/1/2023. Episodes were excluded if fulminant, patient was transferred before end of therapy (EOT), or if patient had a preceding CDI in the prior 6 months. The primary outcomes were CDI treatment choice and cure rates. Secondary outcomes included CDI risk factors, change in therapy, recurrence rate, and concurrent positive stool results. Descriptive statistics were performed. Results There were 20 CDI episodes in the pre- and 24 in the post-intervention period. Baseline characteristics and CDI risk factors were similar (Table 1). Most patients underwent allogeneic HCT for malignancy, and most CDI occurred within 10 days of CT. All but 1 patient had preceding antibiotic exposure. Initial CDI treatment was enteral vancomycin in most patients pre- (90%) and post-intervention (79.2%) (Table 2). Intravenous (IV) metronidazole was the second most common initial treatment, and the most frequent drug when therapy was changed. Fidaxomicin use was uncommon. Clinical cure was achieved in 85% vs 75% of episodes, and 8-week recurrence was rare, occurring in 5% vs 8.3% of episodes pre- and post-intervention. Conclusion Despite de-restriction, use of fidaxomicin in cellular therapy patients at CHLA remains uncommon versus enteral vancomycin. Providers were more likely to change therapy to a less optimal second treatment (IV metronidazole), mainly for oral drug intolerance. Additional education and a CT population-specific CDI guideline are needed to optimize treatment. Limitations include low sample size, lack of C. difficile toxin PCR testing, and possible underestimation of recurrences due to 8-week follow up period. Future studies will assess outpatient CDI episodes and treatments used for CT patients with recurrent CDI episodes within 3-6 months.
Reference Key
openalex_W7204633069 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Andrew Karnaze, Darra Drucker, Regina Orbach, Leila C. Posch
Are you one of these authors? Claim your profile
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.068
URL
https://academic.oup.com/jpids/article-pdf/15/Supplement_2/S29/70833325/piag070.068.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.